Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Aug 7, 2008

Ore Pharmaceuticals Obtains Second Candidate from Roche for Repositioning

  • Ore Pharmaceuticals acquired the exclusive rights for one of Roche’s abandoned clinical-stage compounds to develop the candidate in metabolic diseases. Romazarit was being investigated by Roche as an anti-inflammatory and had reached Phase II trials for rheumatoid arthritis.

    Repositioning efforts at Ore Pharmaceuticals discovered that romazarit modulates a key pathway related to metabolic function. The firm then identified potentially novel therapeutic uses for romazarit in metabolic diseases and subsequently observed a lowering of lipids, weight, and glucose levels through in vivo testing.

    Ore Pharmaceuticals will now select the most appropriate of the potential indications and prepare for Phase II trials. It will also engage in out-licensing efforts.

    Ore Pharmaceuticals recently took over the rights to cardiovascular treatment candidate tiapamil from Roche for development in central nervous system diseases.

Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »